China’s generative artificial intelligence (AI)-driven biotech firm, Insilico Medicine, has announced the first patient dosing in a Phase I clinical study for ISM8207, a potential first-in-class drug candidate co-developed with Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196).
The open-label, multi-center Phase I study aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ISM8207 in patients with refractory/recurrent lymphoma and other advanced solid tumors. It will also explore the recommended effective dose for subsequent phases during the dosage escalation part.
ISM8207 is a small molecule inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL), an enzyme that plays a crucial role in CD47 pyroglutamate formation. This modification is essential for the interaction of CD47 with its ligand SIRPα, a mechanism that tumor cells exploit to evade the human immune system. CD47 is over-expressed on a broad spectrum of cancer types. QPCTL also regulates various chemokines related to the immunosuppressive tumor microenvironment during post-translational modification. Preclinical studies have demonstrated that ISM8207 possesses favorable pharmacokinetic properties and exhibits significant synergistic anti-tumor effects when combined with other drugs.- Flcube.com
